TRexBio raises $116.7 million in IPO for autoimmune disease treatments
TRexBio Inc., an early-stage biotech company focused on autoimmune and inflammatory diseases, raised $116.7 million in a US initial public offering that priced at the bottom of its marketed range.
·2 sources
